MILANOVA TSVETA (Chief Commercial Officer) sold 6.5% of their position (3.26K shares) of AGIOS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $113.2K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/6/2026ACC: 0001439222-26-000061
Officer· Chief Commercial Officer
Since Mar 2026
-3.26K
Net shares
Net seller
$113.2K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
8.50K acquired · 11.76K disposed
Non-Derivative Transactions2
Common stock
Direct
Shares
+8.50K
Price / share
—
Trade value
—
% of position
20.4%
4/2/2026
41.59K→50.09K
Common stock
Direct
Shares
−3.26K
Price / share
$34.71
Trade value
$113.22K
% of position
6.5%
4/2/2026
50.09K→46.83K
Total
Net shares
+5.24K
Net value
-$113.22K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock Direct | 4/2/2026 | M · Option Exercise | +8.50K | — | — | 20.4% | 41.59K | 50.09K |
| Common stock Direct | 4/2/2026 | S · Sale | −3.26K | $34.71 | $113.22K | 6.5% | 50.09K | 46.83K |
| Total | +5.24K | -$113.22K | ||||||
Derivative Transactions1
Performance share units
Direct
Converts to
Common stock
8.50K shares
Shares
−8.50K
Strike price
Held after
8.50K
Exercisable
—
4/2/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Performance share units Direct | Common stock8.50K shares | 4/2/2026 | M · Option Exercise | −8.50K | — | 8.50K |